久在草_国产精品久久久久久久久免费樱桃_欧美婷婷色_日韩成人在线影院_永久免费精品视频_欧美精品免费一区欧美久久优播

加入收藏 | 設為首頁 | 聯系我們

產品搜索

聯系我們

聯系人:蔣經理
電話:4008750250
號碼:
手機:18066071954
地址:南京市棲霞區緯地路9號
Email: [email protected]

產品展示 / PRODUCTS
藥靶細胞株 > kinase激酶細胞株 > CBP73205KIF5B(E15)-RET(E12)-Short/BaF3

KIF5B(E15)-RET(E12)-Short/BaF3
名稱 KIF5B(E15)-RET(E12)-Short/BaF3
型號 CBP73205
報價
特點 KIF5B(E15)-RET(E12)-Short/BaF3,母細胞:BaF3,凍存條件:90% FBS+10% DMSO
  • 詳細內容
CBP73205
I. Introduction

Cell Line Name:

KIF5B(E15)-RET(E12)-Short/BaF3

Host Cell:

Ba/F3

Stability:16 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.)

Application:

Anti-proliferation assay and PD assay

Freeze Medium:

90% FBS+10% DMSO

Complete Culture Medium:

RPMI-1640+10%FBS+1 ug/ml puromycin

Mycoplasma Status:

Negative


II.Background

Chromosomal rearrangements involving the gene that encodes the RET tyrosine kinase are known oncogenic drivers in 1% to 2% of patients with non–small cell lung cancer (NSCLC). These RET rearrangements occur with characteristic partners, most commonly KIF5B, but also CCDC6, NCOA, TRIM33, CUX1, KIAA1217, FRMD4A, and KIAA1468. They are typically identified in young patients with adenocarcinoma histology and minimal smoking history. Therapeutic targeting of RET-fusion–driven NSCLCs has taken the form of treatment with broad-spectrum tyrosine kinase inhibitors with anti-RET activity, such as cabozantinib (Cabometyx; Cometriq), vandetanib (Caprelsa), lenvatinib (Lenvima), RXDX-105, and sunitinib (Sutent). Cabozantinib and vandetanib have been the most heavily studied multi-kinase inhibitors (MKIs), with response rates of 20% to 50% in largely pretreated patients with RET-rearranged NSCLC. Sunitinib has been used in fewer patients to date with initial results demonstrating a 22% response rate. RXDX-105 has exhibited uniquely impressive response rates (75%) in patients with non–KIF5B-RET-fusion NSCLC, compared with 0% response in patients with KIF5B-RET-fusion–positive NSCLC. BLU-667 has demonstrated an objective response rate of 50% in patients with RET-fusion positive NSCLC, and LOXO-292 reported a 74% ORR in patients with RET-fusion positive NSCLC. Notably, RXDX-105, BLU- 667, and LOXO-292 have all demonstrated some central nervous system activity in these early phase trials. Future directions of RET inhibition in patients with RET-rearranged NSCLC include additional clinical validation of the next generation RET-selective inhibitors RXDX-105, BLU-667, and LOXO-292 and comparing multikinase inhibitors with RET-selective inhibitors to determine the optimal sequencing of RET-targeted therapies.


III. Representative Data

1. WB of KIF5B-RET (K15, R12S)/BaF3

CBP73205 WB.jpg


2. Sanger of KIF5B-RET (K15, R12S)/BaF3

CBP73205 sanger1.png


CBP73205 sanger2.png


3. Anti-proliferation assay

CBP73205 fig.jpg

Figure 4. CTG Proliferation Assay of BaF3 KIF5B-Ret (s) Cells (C6).




如果你對CBP73205KIF5B(E15)-RET(E12)-Short/BaF3感興趣,想了解更詳細的產品信息,填寫下表直接與廠家聯系:


留言框

  • 產品:

  • 您的單位:

  • 您的姓名:

  • 聯系電話:

  • 常用郵箱:

  • 省份:

  • 詳細地址:

  • 補充說明:

  • 驗證碼:

    請輸入計算結果(填寫阿拉伯數字),如:三加四=7

化工儀器網

推薦收藏該企業網站
主站蜘蛛池模板: 亚洲欧美二区三区久本道 | 国产亚洲精品高清在线 | 亚洲午夜在线 | 武松2013 | 久草在线在线精品观看 | 免费一级欧美毛片 | 在线视频中文字幕乱人伦 | 小明永久视频免费播放 | 色综合网亚洲精品久久久 | 91福利小视频| 欧美一区精品 | 窝窝午夜精品一区二区 | 偷拍自拍一区 | 欧美成人精品二区三区99精品 | 日本在线观看中文字幕 | 伊人伊人 | 久久久久草 | 中国在线播放精品区 | 国产免费网址 | 香蕉久久网 | 在线成人免费 | 久久我们这里只有精品国产4 | 伊人a.v在线 | 亚洲欧美第一视频 | 国产大片在线观看 | 久久涩综合 | 成人精品久久 | 久久中文字幕网 | 亚洲成在人线中文字幕 | 99精品国产在热久久 | 成人一级黄色大片 | aa国产视频一区二区 | 午夜精品在线视频 | 操出白浆在线观看 | 日日夜夜操操操 | 色狠狠成人综合色 | 精品一本久久中文字幕 | 亚洲欧美中文日韩在线v日本 | 久久综合婷婷香五月 | 亚洲精品成人AA片在线播 | 欧美在线观看视频一区 |